CXCR2 and neoplasm: In agreement, Dox also exhibited better therapeutic efficacy in Cxcr2–/– and Cfb–/– mice with reduced tumor growth and decreased tumoral NET level (Figure 3, P and Q, and Supplemental Figure 7F).